Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma ...Middle East

THOUSAND OAKS, Calif., Dec. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with...

Hence then, the article about update on source phase 3 trial for tezepelumab in patients with severe oral corticosteroid dependent asthma was published today ( Tuesday 22/12/2020 - 11:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma )

Also on site :

• Man Notices Small Lump on Knee, Then Faces Life-Saving Decision
• Legendary Music Icon Surprises Fans With a Jaw-Dropping Announcement 30 Years in the Making
• KDDI to conduct AI drone feasibility study in Vietnam and the Philippines